KR20240125003A - Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법 - Google Patents

Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법 Download PDF

Info

Publication number
KR20240125003A
KR20240125003A KR1020247024147A KR20247024147A KR20240125003A KR 20240125003 A KR20240125003 A KR 20240125003A KR 1020247024147 A KR1020247024147 A KR 1020247024147A KR 20247024147 A KR20247024147 A KR 20247024147A KR 20240125003 A KR20240125003 A KR 20240125003A
Authority
KR
South Korea
Prior art keywords
methyl
characteristic peaks
powder
salt
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247024147A
Other languages
English (en)
Korean (ko)
Inventor
웨이동 루
구쥔 쉬
쥔란 양
치윈 샤오
전싱 두
쥔 펑
펑 허
Original Assignee
지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
샹하이 헨그루이 파마수티컬 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드, 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 filed Critical 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드
Publication of KR20240125003A publication Critical patent/KR20240125003A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/12—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic the nitrogen atom of the amino group being further bound to hydrocarbon groups substituted by hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
    • C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020247024147A 2021-12-23 2022-12-23 Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법 Pending KR20240125003A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202111584574 2021-12-23
CN202111584574.4 2021-12-23
PCT/CN2022/141418 WO2023116882A1 (zh) 2021-12-23 2022-12-23 一种glp-1受体激动剂的可药用盐、结晶形式及其制备方法

Publications (1)

Publication Number Publication Date
KR20240125003A true KR20240125003A (ko) 2024-08-19

Family

ID=86901360

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247024147A Pending KR20240125003A (ko) 2021-12-23 2022-12-23 Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법

Country Status (11)

Country Link
US (1) US20250049777A1 (https=)
EP (2) EP4455141B1 (https=)
JP (1) JP2024547113A (https=)
KR (1) KR20240125003A (https=)
CN (1) CN118434730A (https=)
AU (1) AU2022418658A1 (https=)
CA (1) CA3241670A1 (https=)
DK (1) DK4455141T3 (https=)
MX (1) MX2024007906A (https=)
TW (1) TW202328114A (https=)
WO (1) WO2023116882A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120981457A (zh) 2023-09-14 2025-11-18 歌礼制药(中国)有限公司 Glp-1r激动剂及其治疗方法
TW202521534A (zh) 2023-11-24 2025-06-01 香港商歌禮製藥(中國)有限公司 Glp-1r 激動劑及其治療方法
WO2025148954A1 (zh) * 2024-01-09 2025-07-17 山东盛迪医药有限公司 一种glp-1r激动剂药物组合物及其应用
TW202600132A (zh) 2024-03-08 2026-01-01 美商安尼波那生物公司 用於治療肥胖症及提高減重之方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10934279B2 (en) * 2018-06-13 2021-03-02 Pfizer Inc. GLP-1 receptor agonists and uses thereof
MA54555A (fr) * 2018-11-22 2021-09-29 Qilu Regor Therapeutics Inc Agonistes de glp-1r et leurs utilisations
CN115697338B (zh) * 2020-06-10 2024-08-09 东宝紫星(杭州)生物医药有限公司 甲基取代的苯并二噁唑类化合物及其应用
CA3188891A1 (en) * 2020-09-01 2022-01-13 Fanglong Yang Fused imidazole derivative, preparation method therefor, and medical use thereof
CN117177970A (zh) * 2021-04-30 2023-12-05 上海翰森生物医药科技有限公司 多环类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
TW202328114A (zh) 2023-07-16
EP4732838A2 (en) 2026-04-29
MX2024007906A (es) 2024-07-10
AU2022418658A1 (en) 2024-07-11
CN118434730A (zh) 2024-08-02
EP4455141B1 (en) 2026-03-25
EP4455141A1 (en) 2024-10-30
DK4455141T3 (da) 2026-04-27
EP4455141A4 (en) 2025-04-09
CA3241670A1 (en) 2023-06-29
JP2024547113A (ja) 2024-12-26
US20250049777A1 (en) 2025-02-13
WO2023116882A1 (zh) 2023-06-29

Similar Documents

Publication Publication Date Title
KR20240125003A (ko) Glp-1 수용체 작용제의 약학적으로 허용 가능한 염, 결정 형태 및 이의 제조방법
KR20240125004A (ko) Glp-1 수용체 작용제의 결정 형태 및 이의 제조방법
CN113993845A (zh) 作为治疗cns障碍例如多发性硬化的gpr17调节剂的n-(苯基)-吲哚-3-磺酰胺衍生物和相关化合物
TW202220962A (zh) 選擇性NaV抑制劑的結晶形式及其製備方法
TW202043233A (zh) 1,2,3-三氮唑并[1,5-a]吡類衍生物的晶型及其製備方法
US20250361226A1 (en) Pharmaceutically acceptable salt of benzo[c]chroman compound and polymorphic form and use of pharmaceutically acceptable salt
US20250353839A1 (en) Polymorph of benzo[c]chroman compound, preparation method therefor and use thereof
WO2024193455A1 (zh) 一种1,4-二氢-1,6-萘啶酰胺化合物的可药用盐、晶型及其制备方法
TW202408504A (zh) 噻吩[2,3-d]咪唑類化合物的鹽及其晶型和在醫藥上的用途
CN118355000A (zh) 二甲基亚磺酰亚胺衍生物的盐型及晶型
WO2022127904A1 (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法
TWI914461B (zh) 一種吲唑類衍生物的藥學上可接受鹽、結晶形式及其製備方法
TW202333694A (zh) 稠環衍生物的晶型、其製備方法及其應用
WO2025131045A1 (zh) 一种taar1配体激动剂的盐型、晶型及其制备方法和应用
WO2026082108A1 (zh) 一种nlrp3抑制剂用于治疗帕金森病或帕金森综合征的用途
WO2023151660A1 (zh) 一种p2x3受体拮抗剂的结晶形式及其制备方法
TW202411218A (zh) 羥肟酸酯化合物及其鹽的結晶形式與製備方法
WO2021175225A1 (zh) 三环类化合物及其应用
CN116437917A (zh) Atx抑制剂氘代衍生物及其应用
HK40062458A (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
CN114644616A (zh) 一种吲唑类衍生物的药学上可接受的盐、结晶形式及其制备方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE)

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000